Freeman Technology highlights relevance of the FT4 for DPI characterisation

Published: 2-Mar-2010
Manufacturing Regulatory Drug Delivery Analysis Pharmaceutical

Respiratory Drug Delivery (RDD) 2010, 25 - 29 April 2010, Florida, US

At Respiratory Drug Delivery (RDD) 2010, Freeman Technology will highlight the unique insight the FT4 Powder Rheometer offers DPI formulators. This message will be reinforced by a presentation of work from the University of Bath showing a direct correlation between the measured dynamic powder properties and fine particle dose (FPD), a measure of drug delivery efficiency.

Dynamic powder characterization with the FT4 directly quantifies powder flowability and the response of a formulation to air, a critical property for successful DPI development. To ensure efficient drug delivery a DPI formulation/device combination must be engineered to achieve aerosolisation of the dose to a respirable size during use.

Research at the University of Bath has shown a robust correlation between FPD and aerated energy, a measure of how the flowability of the powder changes with the amount of air flowing through it. This makes the FT4 an extremely useful tool for the development of DPI formulations, which are required to disperse easily, with more consistent and less patient dependent performance.

The FT4 combines dynamic testing methodologies with shear and bulk property measurement, to provide comprehensive, process relevant powder characterisation. Precision engineering in combination with well-defined, automated test procedures deliver exceptional reproducibility and sensitivity. With application know-how that has been gained from 10 years working with industry, Freeman Technology also provides extensive powder processing expertise alongside the FT4 Powder Rheometer.
See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Accelerating the development of bispecific antibodies

Read more
Sherry Gu, Executive Vice President and CTO at WuXi Biologics, explains how the use of comprehensive tailored approaches can enhance bispecific antibody productivity, stability and quality while accelerating their delivery to market

Trending Articles

  1. Adragos Pharma acquires Sanofi's Maisons-Alfort sterile fill-finish facility to strengthen European injectables network Global CDMO Adragos Pharma has completed the acquisition of one of Europe's largest sterile injectables manufacturing sites from Sanofi in Maisons-Alfort, France, adding high-volume pre-filled syringe capabilities to its existing fill-finish operations in Switzerland and Livron
  2. Swiss Rockets collaborates with Lonza to advance Torqur’s oncology drug candidate bimiralisib into late-stage clinical development Lonza to provide cGMP manufacturing and technical support to advance bimiralisib into late-stage clinical development
  3. FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions Eli Lilly has received FDA approval for Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight that requires no fasting or water restrictions, with clinical trial participants on the highest dose losing an average of 27 pounds

Upcoming event

Making Pharmaceuticals

21–22 April 2026 | Exhibition | Coventry, UK See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Accelerating the development of bispecific antibodies

Sherry Gu, Executive Vice President and CTO at WuXi Biologics, explains how the use of comprehensive tailored approaches can enhance bispecific antibody productivity, stability and quality while accelerating their delivery to market
Analysis

Conjugation chemistry key to unlocking next-generation oligonucleotide therapies, says Bachem

As demand for oligonucleotide therapeutics accelerates, Bachem's Director of Oligonucleotide Production explains how conjugation chemistry is helping CDMOs overcome delivery challenges
Manufacturing

UK pharmaceutical manufacturers struggling to meet F-Gas compliance amid ageing cooling infrastructure

A new Aggreko report reveals that nearly all UK pharmaceutical manufacturers are facing barriers to upgrading cooling systems ahead of the accelerating F-Gas phase-down timeline
Regulatory

UK REACH ATRm: CBA welcomes progress but warns of significant hurdles ahead

The Chemical Business Association has acknowledged long-awaited movement on the UK REACH Alternative Transitional Registration model following DEFRA's consultation response, but cautioned that cost burdens likely running into hundreds of millions of pounds
Manufacturing

Labtex - Fresh thinking and innovative solutions

Labtex states: "We are proud to provide unique solutions for laboratories and pilot plants across the UK"
Regulatory

Lonza Nominates Stephen Fry as Independent Board Member

Basel, Switzerland, 31 March 2026 – The Lonza Board of Directors today announced the nomination of Stephen Fry as an Independent Member of the Board. Subject to his election at the Lonza Group Annual General Meeting (AGM) in May 2026, Stephen will also be appointed a member of the People and Governance Committee and the Audit and Compliance Committeex
Manufacturing

Nemera partners with Therakind to expand nasal drug delivery portfolio with DriDose dry powder platform

The manufacturer has announced a strategic partnership with UK pharmaceutical company Therakind to advance the DriDose intranasal dry powder platform, adding dry powder delivery capabilities to complement Nemera's existing liquid nasal formulation offering
Subscribe now